CTIC - シ―ティ―アイ・バイオファ―マ (CTI BioPharma Corp.) シ―ティ―アイ・バイオファ―マ

 CTICのチャート


 CTICの企業情報

symbol CTIC
会社名 CTI BioPharma Corp (シ―ティ―アイ・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 CTIバイオファーマ(CTI BioPharma Corp. )(旧称:Cell Therapeutics Inc.)は癌を治療する毒性の少ない方法の取得・開発・商品化に焦点を当てるバイオ医薬品会社。同社は満たされていない医療ニーズのある血液関連癌向けの治療に力を集中する。同社は主に再発乗算または難治性の積極的な非ホジキンリンパ腫(NHL)のために、欧州連合でPIXUVRI(ピクサントロン)の商品化に従事する他、骨髄線維症の治療用pacritinibの第三相臨床試験を実行する。PIXUVRIは新規アザ・アントラセンジオン誘導体であり、構造的にアントラサイクリン及びアントラセンジオンに関連するが、心毒性作用の同じレベルに関連すると表示されない。   シ―ティ―アイ・バイオファ―マは、米国のバイオ医薬品会社。癌治療法の取得、開発、商業化に従事する。欧州地方で非ホジキンリンパ腫治療の「PIXUVRI(ピクサントロン)」を商品化することに焦点を当てる。血液関連癌のスペクトルをカバ―する新たな治療標的を当てるほか癌と共に生きる人々のための治療選択肢の開発も展開する。   CTI BioPharma Corp. is a biopharmaceutical company, which focuses on the development, acquisition and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.
本社所在地 3101 Western Avenue Suite 600 Seattle WA 98121 USA
代表者氏名
代表者役職名
電話番号 +1 206-282-7100
設立年月日 33482
市場名 NASDAQ Small Cap
ipoyear 1997年
従業員数 149人
url www.celltherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/ctic
adr_tso
EBITDA EBITDA(百万ドル) -43.17000
終値(lastsale) 2.05
時価総額(marketcap) 118877294.2
時価総額 時価総額(百万ドル) 118.87730
売上高 売上高(百万ドル) 13.25700
企業価値(EV) 企業価値(EV)(百万ドル) 40.31630
当期純利益 当期純利益(百万ドル) -41.67700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 CTI BioPharma Corp revenues decreased 52% to $11.1M. Net loss applicable to common stockholders decreased 18% to $15.4M. Revenues reflect License and contract revenue decrease of 49% to $11.1M Product sales net decrease from $1M to $0K. Lower net loss reflects Other selling general decrease of 47% to $8.4M (expense) Other non-operating income (expense) increase from $30K (expense) to $4.7M (income).

 CTICのテクニカル分析


 CTICのニュース

   CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial  2020/06/01 11:00:00 PR Newswire
/PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of…
   CTI BioPharma to Present at the Jefferies 2020 Healthcare Conference on Thursday, Jun. 4  2020/05/28 11:00:00 PR Newswire
SEATTLE, May 28, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare Conference at 2:30 p.m. EDT. The conference will be held in a virtual meeting format. Presentation…
   CTI BioPharma Reports First Quarter 2020 Financial Results  2020/05/07 20:05:00 PR Newswire
SEATTLE, May 7, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2020. "With a sufficient cash runway into Q4 2021, we have the resources to continue to advance pacritinib as quickly as possible as a…
   Primary Myelofibrosis Pipeline Landscape Analysis, 2020 Featuring Novartis, Geron Corporation, NS Pharma, Actuate Therapeutics, Suzhou Zelgen Biopharmaceuticals, CTI BioPharma, Covance, and More - ResearchAndMarkets.com  2020/04/20 15:50:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Primary Myelofibrosis - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Primary Myelofibrosis Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Primary Myelofibrosis market. A detailed picture of the Primary Myelofibrosis pipeline landscape is provided, which includes the disease overview and Primary Myelofibrosis treatment guidelines. The assess
   CTI BioPharma Announces Commencement of Rights Offering  2020/02/14 12:00:00 PR Newswire
SEATTLE, Feb. 14, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today commenced its previously announced rights offering to raise gross proceeds of approximately $60.0 million (the "Rights Offering"). Under the terms of the Rights Offering, the holders, as of 5:00 p.m., New York…
   CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial  2020/06/01 11:00:00 PR Newswire
/PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of…
   CTI BioPharma to Present at the Jefferies 2020 Healthcare Conference on Thursday, Jun. 4  2020/05/28 11:00:00 PR Newswire
SEATTLE, May 28, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare Conference at 2:30 p.m. EDT. The conference will be held in a virtual meeting format. Presentation…
   CTI BioPharma Reports First Quarter 2020 Financial Results  2020/05/07 20:05:00 PR Newswire
SEATTLE, May 7, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2020. "With a sufficient cash runway into Q4 2021, we have the resources to continue to advance pacritinib as quickly as possible as a…
   Primary Myelofibrosis Pipeline Landscape Analysis, 2020 Featuring Novartis, Geron Corporation, NS Pharma, Actuate Therapeutics, Suzhou Zelgen Biopharmaceuticals, CTI BioPharma, Covance, and More - ResearchAndMarkets.com  2020/04/20 15:50:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Primary Myelofibrosis - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Primary Myelofibrosis Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Primary Myelofibrosis market. A detailed picture of the Primary Myelofibrosis pipeline landscape is provided, which includes the disease overview and Primary Myelofibrosis treatment guidelines. The assess
   CTI BioPharma Announces Commencement of Rights Offering  2020/02/14 12:00:00 PR Newswire
SEATTLE, Feb. 14, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today commenced its previously announced rights offering to raise gross proceeds of approximately $60.0 million (the "Rights Offering"). Under the terms of the Rights Offering, the holders, as of 5:00 p.m., New York…
   CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial  2020/06/01 11:00:00 PR Newswire
/PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of…
   CTI BioPharma to Present at the Jefferies 2020 Healthcare Conference on Thursday, Jun. 4  2020/05/28 11:00:00 PR Newswire
SEATTLE, May 28, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare Conference at 2:30 p.m. EDT. The conference will be held in a virtual meeting format. Presentation…
   CTI BioPharma Reports First Quarter 2020 Financial Results  2020/05/07 20:05:00 PR Newswire
SEATTLE, May 7, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2020. "With a sufficient cash runway into Q4 2021, we have the resources to continue to advance pacritinib as quickly as possible as a…
   Primary Myelofibrosis Pipeline Landscape Analysis, 2020 Featuring Novartis, Geron Corporation, NS Pharma, Actuate Therapeutics, Suzhou Zelgen Biopharmaceuticals, CTI BioPharma, Covance, and More - ResearchAndMarkets.com  2020/04/20 15:50:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Primary Myelofibrosis - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Primary Myelofibrosis Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Primary Myelofibrosis market. A detailed picture of the Primary Myelofibrosis pipeline landscape is provided, which includes the disease overview and Primary Myelofibrosis treatment guidelines. The assess
   CTI BioPharma Announces Commencement of Rights Offering  2020/02/14 12:00:00 PR Newswire
SEATTLE, Feb. 14, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today commenced its previously announced rights offering to raise gross proceeds of approximately $60.0 million (the "Rights Offering"). Under the terms of the Rights Offering, the holders, as of 5:00 p.m., New York…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 シ―ティ―アイ・バイオファ―マ CTIC CTI BioPharma Corp.)

 twitter  (公式ツイッターやCEOツイッターなど)